Gunnar Folprecht

Summary

Country: Germany

Publications

  1. ncbi request reprint Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting
    Gunnar Folprecht
    Medical Department I, Carl Gustav Carus University Hospital of Dresden, Fetscherstrasse 74, 01307 Dresden, Germany
    Nat Clin Pract Oncol 2:578-87. 2005
  2. ncbi request reprint Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
    Gunnar Folprecht
    Medical Department I, University Hospital Carl Gustav Carus, University Cancer Center, Fetscherstr 74, 01307 Dresden, Germany
    BMC Cancer 14:521. 2014
  3. doi request reprint [Computed tomographic morphological evaluation of neoadjuvant chemotherapy. Effectiveness of the therapy for colorectal liver metastases]
    G Folprecht
    Medizinische Klinik und Poliklinik I, Universitätskrebszentrum, Universitatsklinikum Carl Gustav Carus, Fetscherstr 74, 01307, Dresden, Deutschland
    Chirurg 85:31-6. 2014
  4. pmc Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Birgit Luber
    Institut für allgemeine Pathologie und pathologische Anatomie, Technische Universitat Munchen, Trogerstraße 18, 81675 Munchen, Germany
    BMC Cancer 11:509. 2011
  5. doi request reprint [Neoadjuvant therapy concepts for liver metastases]
    G Folprecht
    Universitätskrebszentrum Medizinische Klinik und Poliklinik I, Universitatsklinikum Carl Gustav Carus, Fetscherstr 74, 01307, Dresden, Deutschland
    Chirurg 82:989-94. 2011
  6. doi request reprint [Current medicinal treatment of metastasized colorectal carcinoma]
    G Folprecht
    Universitätskrebszentrum Medizinische Klinik I, Universitatsklinikum Carl Gustav Carus, Fetscherstrasse 74, Dresden, Germany
    Chirurg 81:507-15. 2010
  7. doi request reprint Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
    Gunnar Folprecht
    University Hospital Carl Gustav Carus, Medical Department I University Cancer Center, Dresden, Germany
    Lancet Oncol 11:38-47. 2010
  8. doi request reprint Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials
    Gunnar Folprecht
    University Hospital Dresden, Fetscherstr 74, Dresden, Germany 01307
    J Clin Oncol 26:1443-51. 2008
  9. ncbi request reprint Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with
    Gunnar Folprecht
    Medical Department I, University Hospital Carl Gustav Carus, Dresden, Germany
    Clin Cancer Res 14:215-23. 2008
  10. ncbi request reprint [New therapy options in colorectal carcinoma]
    G Folprecht
    Medizinische Klinik I, Universitatsklinikum Carl Gustav Carus, Dresden
    Ther Umsch 61:373-8. 2004

Detail Information

Publications26

  1. ncbi request reprint Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting
    Gunnar Folprecht
    Medical Department I, Carl Gustav Carus University Hospital of Dresden, Fetscherstrasse 74, 01307 Dresden, Germany
    Nat Clin Pract Oncol 2:578-87. 2005
    ....
  2. ncbi request reprint Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
    Gunnar Folprecht
    Medical Department I, University Hospital Carl Gustav Carus, University Cancer Center, Fetscherstr 74, 01307 Dresden, Germany
    BMC Cancer 14:521. 2014
    ..Adding cetuximab to FOLFOX or FOLFIRI increased efficacy in patients with k-ras wild type mCRC. We explored the dose limiting toxicity and feasibility of the combination cetuximab, irinotecan, oxaliplatin, 5-FU and FA in mCRC patients...
  3. doi request reprint [Computed tomographic morphological evaluation of neoadjuvant chemotherapy. Effectiveness of the therapy for colorectal liver metastases]
    G Folprecht
    Medizinische Klinik und Poliklinik I, Universitätskrebszentrum, Universitatsklinikum Carl Gustav Carus, Fetscherstr 74, 01307, Dresden, Deutschland
    Chirurg 85:31-6. 2014
    ..Studies have shown that the response rate during neoadjuvant conversion chemotherapy is closely correlated with the frequency of resection of metastases...
  4. pmc Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Birgit Luber
    Institut für allgemeine Pathologie und pathologische Anatomie, Technische Universitat Munchen, Trogerstraße 18, 81675 Munchen, Germany
    BMC Cancer 11:509. 2011
    ....
  5. doi request reprint [Neoadjuvant therapy concepts for liver metastases]
    G Folprecht
    Universitätskrebszentrum Medizinische Klinik und Poliklinik I, Universitatsklinikum Carl Gustav Carus, Fetscherstr 74, 01307, Dresden, Deutschland
    Chirurg 82:989-94. 2011
    ..Operations should be planned as soon as resectability is achieved because a longer therapy will increase morbidity and because of uncertainty over the approach to patients with complete remission...
  6. doi request reprint [Current medicinal treatment of metastasized colorectal carcinoma]
    G Folprecht
    Universitätskrebszentrum Medizinische Klinik I, Universitatsklinikum Carl Gustav Carus, Fetscherstrasse 74, Dresden, Germany
    Chirurg 81:507-15. 2010
    ..g. neoadjuvant treatment of non-resectable liver metastases), tumor symptoms which urgently require a tumor response and comorbidities...
  7. doi request reprint Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
    Gunnar Folprecht
    University Hospital Carl Gustav Carus, Medical Department I University Cancer Center, Dresden, Germany
    Lancet Oncol 11:38-47. 2010
    ..Neoadjuvant chemotherapy for unresectable colorectal liver metastases can downsize tumours for curative resection. We assessed the effectiveness of cetuximab combined with chemotherapy in this setting...
  8. doi request reprint Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials
    Gunnar Folprecht
    University Hospital Dresden, Fetscherstr 74, Dresden, Germany 01307
    J Clin Oncol 26:1443-51. 2008
    ..Uncertainty exists about whether elderly patients benefit to the same extent as younger patients from combination therapy with irinotecan in the first-line treatment of metastatic colorectal cancer (CRC)...
  9. ncbi request reprint Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with
    Gunnar Folprecht
    Medical Department I, University Hospital Carl Gustav Carus, Dresden, Germany
    Clin Cancer Res 14:215-23. 2008
    ..To determine the recommended dose (RD) of EKB-569, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer (mCRC)...
  10. ncbi request reprint [New therapy options in colorectal carcinoma]
    G Folprecht
    Medizinische Klinik I, Universitatsklinikum Carl Gustav Carus, Dresden
    Ther Umsch 61:373-8. 2004
    ..The additional therapy with the VEGF-antibody bevacizumab prolongs survival by more than 4 months compared to chemotherapy alone. The EGF-receptor antibody cetuximab is an effective therapy after progression with irinotecan...
  11. ncbi request reprint The role of new agents in the treatment of colorectal cancer
    Gunnar Folprecht
    Medical Department I, University Hospital Carl Gustav Carus, Dresden, Germany
    Oncology 66:1-17. 2004
    ..The monoclonal EGF receptor antibody cetuximab alone and in combination with irinotecan is active in second-line treatment. The VEGF antibody bevacizumab prolongs survival when given in combination with 5-FU/FA and irinotecan...
  12. ncbi request reprint [Principles of postoperative therapy in rectal carcinoma]
    G Folprecht
    Medizinische Klinik und Poliklinik I, Universitatsklinikum Carl Gustav Carus, Dresden, Germany
    Chirurg 75:32-7. 2004
    ..These drugs should not be used outside clinical trials. Elderly patients benefit from adjuvant therapy to the same extent as younger patients and should receive adjuvant radiochemotherapy, if no contraindication exists...
  13. pmc Patients' perspectives on palliative chemotherapy of colorectal and non--colorectal cancer: a prospective study in a chemotherapy- experienced population
    Marika Mende
    Medical Department I, University Hospital Carl Gustav Carus, Fetscherstrasse 74, 01307, Dresden, Germany
    BMC Cancer 13:66. 2013
    ..We evaluated palliative cancer patients' reported outcomes (PROs) for toxicity and investigated the survival threshold for which they would repeat chemotherapy (CTx)...
  14. ncbi request reprint Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
    G Folprecht
    University Hospital, Dresden, Germany
    Ann Oncol 17:450-6. 2006
    ..To investigate the safety/tolerability of the EGFR-antibody cetuximab when added to irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) for first-line treatment in patients with metastatic colorectal cancer (mCRC)...
  15. ncbi request reprint Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer
    G Folprecht
    University Hospital Carl Gustav Carus, Dresden, Germany
    Cancer Treat Res 134:425-40. 2007
  16. doi request reprint Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary
    Katharina Schuette
    University Hospital Carl Gustav Carus, Dresden, Germany
    Onkologie 32:162-6. 2009
    ..We performed a phase II study with oxaliplatin (OX) and capecitabine (CAP) as first-line treatment for patients with histo-or cytologically proven adeno- or undifferentiated CUP...
  17. ncbi request reprint Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates
    G Folprecht
    University Hospital Dresden, Germany
    Ann Oncol 16:1311-9. 2005
    ..Recently, an increased number of reports on liver resection following neoadjuvant chemotherapy in patients with initially unresectable liver metastases has been published...
  18. ncbi request reprint Current perspectives in the treatment of metastatic colorectal cancer
    C H Kohne
    University Hospital Dresden, Medical Department I, Germany
    Ann Oncol 15:iv43-53. 2004
  19. ncbi request reprint Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells
    Jana Babatz
    Medizinische Klinik und Poliklinik I, Universitatsklinikum Dresden, Fetscherstr 74, 01307, Dresden, Germany
    Cancer Immunol Immunother 55:268-76. 2006
    ..After incubation with the CEAalt peptide and keyhole limpet hemocyanin, DCs were administered to patients intravenously at dose levels of 1 x 10(7) and 5 x 10(7) cells. Patients received four immunizations every second week...
  20. ncbi request reprint Colorectal liver metastases: an update on palliative treatment options
    Ralf Konopke
    Department of General, Thoracic and Vascular Surgery, University of Technology, Dresden, Germany
    J Gastrointestin Liver Dis 21:83-91. 2012
    ..The present review provides an overview of current colorectal liver metastasis treatment when resection is not an option. This review gives the basis for an interdisciplinary decision making process for the treatment of liver metastasis...
  21. pmc Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational study
    Manja Reimann
    Autonomic and Neuroendocrinological Laboratory, Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, Dresden, Fetscherstr 74, Germany
    Exp Transl Stroke Med 5:7. 2013
    ..To assess acute effects of bevacizumab (anti-VEGF therapy) on cerebral microvessels and systemic cardiovascular regulation...
  22. ncbi request reprint Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials
    G Folprecht
    University Hospital, Dresden, Germany
    Ann Oncol 15:1330-8. 2004
    ....
  23. ncbi request reprint Role of new agents in the treatment of colorectal cancer
    Claus Henning Köhne
    Klinik for Oncology Hematology, Klinikum Oldenburg, Dr Eden Str 10, 26133 Oldenburg, Germany
    Surg Oncol 13:75-81. 2004
    ..e. Cetuximab, Tyrosine kinase inhibitors and Vascular endothelial growth factor receptor inhibitors. This article reviews the above mentioned drugs and includes a recommended approach to chemotherapy in metastatic colorectal cancer...
  24. ncbi request reprint Chemotherapy in elderly patients with colorectal cancer
    Claus Henning Köhne
    Klinik für Onkologie Hämatologie, Klinikum Oldenburg, Dr Eden Str 10, 26133 Oldenburg, Germany
    Oncologist 13:390-402. 2008
    ..The management of frail elderly patients and those with a short life expectancy should be focused on palliation, while fit elderly patients can receive aggressive therapy in a similar fashion to younger patients...
  25. ncbi request reprint Intravitreous bevacizumab and blood pressure: does 'safe' mean 'safe enough'?
    Focke Ziemssen
    Acta Ophthalmol Scand 85:573-4; author reply 574-5. 2007
  26. ncbi request reprint Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization
    Knut Liepe
    Department of Nuclear Medicine, Hospital Kassel, Mönchebergstr 41 43, 34125 Kassel, Germany
    Jpn J Clin Oncol 37:942-50. 2007
    ..This paper describes the feasibility of intra-arterial high-activity administration of (188)Re-microspheres...